Home » Topics » BioWorld Science

BioWorld Science
RSS

Final phase I/Ib study results with Pulmazole support advancement to phase II

Nov. 22, 2018

IBT amends planned phase III protocol for IBP-9414

Nov. 22, 2018

MDM2 degraders for anticancer therapy presented

Nov. 22, 2018

Discovery and characterization of novel potent and selective CD73 inhibitor A-001202

Nov. 22, 2018

FDA approves Daurismo for newly diagnosed AML ineligible for intensive chemotherapy

Nov. 22, 2018

Axxam SpA presents P2X7 receptor antagonists

Nov. 22, 2018

FDA grants accelerated approval to Venclexta for newly diagnosed AML

Nov. 22, 2018

Novartis AG patents new DNA gyrase inhibitors as antibacterials

Nov. 22, 2018

EVT-601, a first-in-class allosteric FGFR antagonist

Nov. 22, 2018

Synthetic announces successful completion of end-of-phase II meeting with FDA regarding ribaxamase

Nov. 22, 2018

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for July 10, 2026.
‘Target-high but uptake-defective’ state identified in ADC resistance
BioWorld
Separate research teams have reported new insights into resistance mechanisms to the antibody-drug conjugate (ADC) Padcev (enfortumab vedotin, Astellas Pharma...
Hyperexcitability may be joint problem in epilepsy, dementia
BioWorld
The majority of epilepsies are developmental disorders that start in childhood. But there is a large minority that starts in late adulthood. And increasingly,...
Neurovalens granted FDA approval for PTSD therapy for US veterans
BioWorld
Veterans in the U.S. suffering from post-traumatic stress disorder (PTSD) now have access to Neurovalens Ltd.’s Modius Spero, a wearable neuromodulation device,...
Ionis, AZ shares down on unexpected Wainua flop in cardiomyopathy
BioWorld
News of the unexpected phase III failure of the gene silencing drug Wainua (eplontersen) in the treatment of transthyretin-mediated amyloid cardiomyopathy sent...